LAWRENCE, Mass., Oct. 3, 2016 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today announced a three-year agreement with Satellite Healthcare that includes NxStage's innovative Nx2me Connected Health® platform for their patients performing home hemodialysis ("HHD") therapy with the NxStage® System One™. Satellite Healthcare is a national not-for-profit and the sixth largest provider of patient-centered dialysis and kidney disease services in the U.S. Under this agreement, Satellite will roll-out the Nx2me Connected Health platform to their HHD patients to enhance patient outcomes and clinician care.
A key component of the Nx2me platform is the Nx2me iPad app, which is designed to increase patients' ease of use of home therapy by monitoring and capturing treatment data and wirelessly sending it to their center after each treatment. Dialysis center staff can access the treatment data using the Nx2me Clinician Portal to review and follow treatment adherence and progress. Importantly, Nx2me patient treatment data can be easily integrated into EMR systems, thereby reducing the need for paper flow sheets. By enhancing the ease of information collection and availability to the patient and care team, Nx2me has been shown to help improve patient retention on HHD. Recent data showed a 44% lower therapy discontinuation rate in new patients using the Nx2me iPad app1.
"This partnership strengthens our Re-Imagine Home goal to change the landscape of home dialysis with the design of an industry-leading home dialysis model," said Satellite Healthcare CEO Rick Barnett. "We identified a number of ways to empower patients, including how technology like Nx2me can be a leading factor in removing barriers to choosing and staying with home dialysis."
"We're delighted that our depth of experience and investment in breakthrough technologies like Nx2me allow us to give Satellite Healthcare additional tools to optimize the way they provide personal care to their patients. We've had a long, successful relationship with Satellite, and are excited to extend the partnership to help Satellite continue to lead by example in the care of home dialysis patients," said Joseph E. Turk, president of NxStage.
For more information about Nx2me and HHD with the NxStage System One, please visit NxStage.com
Despite the health benefits that home hemodialysis may provide to those with chronic kidney disease, this form of therapy is not for everyone. The reported benefits of home hemodialysis may not be experienced by all patients. The risks associated with hemodialysis treatments in any environment include, but are not limited to, high blood pressure, fluid overload, low blood pressure, heart-related issues, and vascular access complications. The medical devices used in hemodialysis therapies may add additional risks including air entering the bloodstream and blood loss due to clotting or accidental disconnection of the blood tubing set. Certain risks are unique to the home. Treatments at home are done without the presence of medical personnel and on-site technical support. Patients and their partners must be trained on what to do and how to get medical or technical help if needed.
1. Weinhandl E, Molina J, Collins A. Lower Risk of Home Hemodialysis Attrition in Patients Using Nx2me Connected Health Technology. Abstract presented at Annual Dialysis Conference. February, 2016.
About Satellite Healthcare
Satellite Healthcare has been among the nation's leading not-for-profit providers of kidney dialysis and related services since 1974. Through its affiliated services, Satellite WellBound, Satellite Dialysis, and Satellite Research, Satellite Healthcare provides unparalleled early patient wellness education, personalized clinical services, and a complete range of dialysis therapy choices. In addition, Satellite Healthcare has a well-recognized, enduring commitment to philanthropy and community service, from funding millions of dollars in research grants to sponsoring kidney programs nationwide. Satellite is committed to advancing the standard of chronic kidney disease care so patients can enjoy a better life.
About the NxStage System One
The NxStage System One is the first and only truly portable hemodialysis system cleared specifically by the FDA for home hemodialysis and home nocturnal hemodialysis. Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy. When combined with the NxStage PureFlow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on demand. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, including while they are sleeping - at home or on vacation and at a medically appropriate treatment frequency. In addition, NxStage's Nx2me Connected Health platform collects important NxStage System One and patient information for flexible viewing, monitoring and reporting that may improve patient management and patient retention, as well as simplify alternative site care. http://www.nxstage.com/.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a leading medical technology company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease (ESRD) and acute kidney failure. NxStage also has established a small number of dialysis clinics committed to the development of innovative care delivery models for patients with ESRD. For more information on NxStage and its products and services, please visit the Company's websites at www.nxstage.com andwww.nxstagekidneycare.com.
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2016. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Kristen K. Sheppard, Esq.
Tel: (978) 332-5923
SOURCE NxStage Medical, Inc.